The abstract is read at the publisher; the summary is JClub's.
Each 10-point increase in total ESAS symptom burden is linked to a 9.4% decrease in 30-day cancer-directed treatment costs in Ontario adults after diagnosis.
- Why it matters: Value in cancer care depends on patient-relevant outcomes per dollar, but the relationship between symptom burden and subsequent health resource use is not well quantified.
- What they did: In a population-based Ontario cohort (2008–2019), 1,728,025 ESAS assessments from 285,924 patients were analyzed using linear regression with log-transformed 30-day costs after ESAS reporting.
- The result: Higher symptom burden predicts lower spending on cancer-directed therapies and higher spending on ancillary health services, supporting PRO-based value measures tied to utilization patterns.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.